Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity

左乙拉西坦 斯特罗普效应 临床痴呆评级 认知 癫痫 随机对照试验 医学 交叉研究 安慰剂 痴呆 心理学 听力学 物理疗法 精神科 疾病 内科学 认知障碍 替代医学 病理
作者
Keith A. Vossel,Kamalini G. Ranasinghe,Alexander J. Beagle,Alice L. La,Kasey Ah Pook,Madelyn R. Castro,Danielle Mizuiri,Susanne M. Honma,Nisha Venkateswaran,MARY E. KOESTLER,Wenbo Zhang,Lennart Mucke,Michael J. Howell,Katherine L. Possin,Joel H. Kramer,Adam L. Boxer,Bruce L. Miller,Srikantan S. Nagarajan,Heidi E. Kirsch
出处
期刊:JAMA Neurology [American Medical Association]
卷期号:78 (11): 1345-1345 被引量:272
标识
DOI:10.1001/jamaneurol.2021.3310
摘要

Importance: Network hyperexcitability may contribute to cognitive dysfunction in patients with Alzheimer disease (AD). Objective: To determine the ability of the antiseizure drug levetiracetam to improve cognition in persons with AD. Design, Setting, and Participants: The Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability (LEV-AD) study was a phase 2a randomized double-blinded placebo-controlled crossover clinical trial of 34 adults with AD that was conducted at the University of California, San Francisco, and the University of Minnesota, Twin Cities, between October 16, 2014, and July 21, 2020. Participants were adults 80 years and younger who had a Mini-Mental State Examination score of 18 points or higher and/or a Clinical Dementia Rating score of less than 2 points. Screening included overnight video electroencephalography and a 1-hour resting magnetoencephalography examination. Interventions: Group A received placebo twice daily for 4 weeks followed by a 4-week washout period, then oral levetiracetam, 125 mg, twice daily for 4 weeks. Group B received treatment using the reverse sequence. Main Outcomes and Measures: The primary outcome was the ability of levetiracetam treatment to improve executive function (measured by the National Institutes of Health Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research [NIH-EXAMINER] composite score). Secondary outcomes were cognition (measured by the Stroop Color and Word Test [Stroop] interference naming subscale and the Alzheimer's Disease Assessment Scale-Cognitive Subscale) and disability. Exploratory outcomes included performance on a virtual route learning test and scores on cognitive and functional tests among participants with epileptiform activity. Results: Of 54 adults assessed for eligibility, 11 did not meet study criteria, and 9 declined to participate. A total of 34 adults (21 women [61.8%]; mean [SD] age, 62.3 [7.7] years) with AD were enrolled and randomized (17 participants to group A and 17 participants to group B). Thirteen participants (38.2%) were categorized as having epileptiform activity. In total, 28 participants (82.4%) completed the study, 10 of whom (35.7%) had epileptiform activity. Overall, treatment with levetiracetam did not change NIH-EXAMINER composite scores (mean difference vs placebo, 0.07 points; 95% CI, -0.18 to 0.32 points; P = .55) or secondary measures. However, among participants with epileptiform activity, levetiracetam treatment improved performance on the Stroop interference naming subscale (net improvement vs placebo, 7.4 points; 95% CI, 0.2-14.7 points; P = .046) and the virtual route learning test (t = 2.36; Cohen f2 = 0.11; P = .02). There were no treatment discontinuations because of adverse events. Conclusions and Relevance: In this randomized clinical trial, levetiracetam was well tolerated and, although it did not improve the primary outcome, in prespecified analysis, levetiracetam improved performance on spatial memory and executive function tasks in patients with AD and epileptiform activity. These exploratory findings warrant further assessment of antiseizure approaches in AD. Trial Registration: ClinicalTrials.gov Identifier: NCT02002819.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
漂亮孤风完成签到,获得积分10
1秒前
张晓祁完成签到,获得积分0
7秒前
大然小怪完成签到 ,获得积分10
7秒前
魁梧的芷完成签到,获得积分10
9秒前
铁瓜李完成签到 ,获得积分10
11秒前
zhzhzh完成签到,获得积分10
12秒前
庄海棠完成签到 ,获得积分0
13秒前
李健的应助被霖29采纳,获得10
19秒前
yueying完成签到,获得积分0
21秒前
xiong xiong完成签到,获得积分10
26秒前
溪泉完成签到,获得积分10
28秒前
32秒前
朴实香氛完成签到,获得积分10
36秒前
Julian的应助被RRui采纳,获得50
37秒前
霖29发布了新的文献求助10
37秒前
38秒前
jacksen2完成签到 ,获得积分10
40秒前
李麟发布了新的文献求助30
43秒前
范yx发布了新的文献求助10
43秒前
司徒诗蕾完成签到 ,获得积分10
43秒前
qiongqiong完成签到 ,获得积分10
45秒前
半颗橙子完成签到 ,获得积分10
46秒前
韩寒123完成签到,获得积分10
46秒前
Omni完成签到,获得积分10
50秒前
Tmac完成签到 ,获得积分10
53秒前
邵邵完成签到,获得积分10
55秒前
zw完成签到 ,获得积分10
55秒前
南村群童完成签到 ,获得积分10
57秒前
Hua完成签到,获得积分10
59秒前
满意的灵枫完成签到 ,获得积分10
1分钟前
666完成签到 ,获得积分10
1分钟前
mhy完成签到 ,获得积分10
1分钟前
cloudehbh完成签到 ,获得积分10
1分钟前
张笨笨完成签到 ,获得积分10
1分钟前
Zoe完成签到,获得积分10
1分钟前
木子完成签到 ,获得积分10
1分钟前
活力的鹰完成签到 ,获得积分10
1分钟前
乐空思的应助被李麟采纳,获得100
1分钟前
嘻嘻哈哈的应助被李麟采纳,获得10
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185520
求助须知:如何正确求助?哪些是违规求助? 9574253
关于积分的说明 21834609
捐赠科研通 7783129
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558951
邀请新用户注册赠送积分活动 2481357